Tue. 11 Jun 2024, 9:12am ET
Benzinga
Biotech, News, General
- Scilex launched its third commercial product, GLOPERBA® on June 10, 2024.
- Scilex has officially shipped its recently approved, GLOPERBA® to many national drug/pharmacy chains, as well as independent pharmacies.
- GLOPERBA® will be the first oral liquid medicine for prophylaxis of gout flares available beginning this week with a WAC Price of $595/bottle.
- Scilex is also in the process of negotiating similar potential stocking arrangements with additional pharmacy chains in the U.S.
- Scilex remains committed to ensuring broad access, awareness and strong supply for broad distribution efforts across the U.S.
- Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is projected to be $2.0 billion in the U.S. by 2028 with a well-defined area of unmet need.